According to the recent research report titled ‘Global Generic Injectables Market (2022 Edition) - Analysis By Molecule Type, (Small, Large), Therapeutic Area, Container Type, By Region, By Country: Market Insights and Forecast with Impact of COVID-19 (2022-2027)’ available with MarketStudyReport, global generic injectables market was valued at USD 134 billion in 2021 and is estimated to generate lucrative returns by the year 2027.

The major factors fueling global generic injectables market are rising number of approvals for generic injectable medicines, growing geriatric population, concerns over expiration of branded drug patents, and an increasing prevalence of life-threatening diseases.

Request sample copy of this report: https://www.marketstudyreport.com/request-a-sample/4814124/

The other factors fueling the overall market size are affordability of generic injectables and their extensive use in treating diseases like cardiovascular diseases, diabetes, and cancer.

The global generic injectables market is segmented based on container type, molecular type, therapeutic value, and regional analysis. The molecular type is further split into small molecules and large molecules segments. Meanwhile, the therapeutic value segment is classified into anti-infectives, cardiovascular diseases, diabetes, oncology, and others.

In terms of regional analysis, the industry is divided into North America, Asia Pacific, Europe, Latin America, and the Middle East & Africa. Among these, Asia Pacific is estimated to emerge as the fastest-growing region in the industry, primarily due to the rise in demand for generic injectables from the Indian companies. Although North America has been predominantly strong in terms of market share and is expected to hold its position in the subsequent years.

The leading companies operating in global generic injectables market are Fresenius SE & Co. KGaA, Pfizer Inc., Gland Pharma Ltd., Teva Pharmaceuticals Ltd., Amneal Pharmaceuticals LLC, Hikma Pharmaceuticals plc, Novartis AG, Sanofi S.A., Baxter International Inc., and Nichi-iko Pharmaceutical Co. Ltd.